Subhashis Banerjee

机构：Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (United States), Vyne Therapeutics (United States), Bristol-Myers Squibb (United Kingdom), Bristol-Myers Squibb (Sweden), Bristol-Myers Squibb (Belgium) · ORCID：0009-0000-1365-5207

发表论文 107 篇 · 总被引 3870 次 · h-index 24

代表论文

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years (2024 · JAMA Dermatology · 被引 51)
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO ‐1, PSO ‐2 and long‐term extension trials (2025 · Journal of the European Academy of Dermatology and Venereology · 被引 37)
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial (2024 · Lara D. Veeken · 被引 12)
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials (2024 · Dermatology and Therapy · 被引 10)
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study (2025 · Lupus Science & Medicine · 被引 7)
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial (2024 · Dermatology and Therapy · 被引 6)